Arbutus Biopharma (ABUS) FCF Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly FCF Margin of 4.53% for Q1 2026, up 75460.0% year-on-year from N/an in Q1 2025, and up 98.98% on a QoQ basis from 445.29% in Q4 2025.
Arbutus Biopharma (ABUS) FCF Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported FCF Margin for 14 consecutive years, with 4.53% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin rose 75460.0% year-over-year to 4.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.95% (up 90401.0% YoY) and the FY2025 annual result came in at 281.45%, up 77238.0% from the prior year.
- FCF Margin improved to 4.53% in Q1 2026 per ABUS's latest filing, from 445.29% in the prior quarter.
- Over the last five years, FCF Margin for ABUS reached as high as 163.29% in Q1 2022 and fell as low as 1548.62% in Q3 2024.
- A 5-year average of 556.75% and a median of 445.29% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 101422 bps — and 2024, when it plunged 108026 bps.
- Year by year, FCF Margin stood at 274.2% in 2022, then plunged by 194 bps to 806.15% in 2023, then gained by 18 bps to 660.8% in 2024, then soared by 33 bps to 445.29% in 2025, then surged by 99 bps to 4.53% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 4.53%, 445.29%, and 1099.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | -4.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.53% |
| Dec 31, 2025 | -445.29% |
| Sep 30, 2025 | -1,099.62% |
| Jun 30, 2025 | -146.65% |
| Mar 31, 2025 | -759.13% |
| Dec 31, 2024 | -660.80% |
| Sep 30, 2024 | -1,548.62% |
| Jun 30, 2024 | -840.38% |
| Mar 31, 2024 | -1,265.67% |
| Dec 31, 2023 | -806.15% |
| Sep 30, 2023 | -468.36% |
| Jun 30, 2023 | -439.00% |
| Mar 31, 2023 | -410.02% |
| Dec 31, 2022 | -274.20% |
| Sep 30, 2022 | -315.57% |
| Jun 30, 2022 | -143.99% |
| Mar 31, 2022 | 163.29% |
| Dec 31, 2021 | -613.35% |
| Sep 30, 2021 | -480.72% |
| Jun 30, 2021 | -628.64% |